An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
about
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsThe Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsPotential role of daratumumab in the treatment of multiple myelomaNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesClinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsCell cycle-regulated protein abundance changes in synchronously proliferating HeLa cells include regulation of pre-mRNA splicing proteinsDesign and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyPhase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibProteasome inhibitor associated thrombotic microangiopathy.A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).The resistance mechanisms of proteasome inhibitor bortezomib.Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib UseA phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaThe proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Targeting ubiquitination for cancer therapies.A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.Emerging therapies targeting the ubiquitin proteasome system in cancerCarfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?Flipping the switch from g1 to s phase with e3 ubiquitin ligases
P2860
Q26741620-B22B518E-7E33-4051-9A62-56AC04BBC501Q26774993-42A02F13-9780-4E7C-A2D9-ADD94D357F31Q26822754-DDF60DD7-4A1E-4C61-8168-19B8DA68B2FDQ26824157-5BEF017E-E597-43D5-B714-4AC6007F22C3Q27004421-169215B2-E95F-4332-974A-DC4E36157D27Q27014143-DB1B59F0-BAE1-4346-ABBB-63D980E64D34Q27026478-C74662B0-18D4-4571-ADC2-EBF2D0BB2C0DQ28080999-FEF3752A-E916-4C80-9F47-E1084520BF05Q28082910-7FF39370-B092-4CA6-96D1-6E776CFB7725Q28084683-B228AD84-2E30-4C33-8322-7EBE45C5C09DQ28487827-E052940C-6A5F-49C1-9374-593412E29468Q31094748-AEA1935D-1766-4DF8-AE9F-6518657DFCE6Q33405181-043AB7F9-F5B9-40DD-9405-6AE8A5BC7EA4Q33405602-C870493B-A1DB-4DBB-AFE8-938CE9F55520Q33406135-03445749-33A5-4EE7-AA23-2C6A3BC62E50Q33409681-0EE90550-7FE6-4D8B-A1C5-090D3162E966Q33410213-1967CC1F-6F8C-4203-994F-B859AEA039B4Q33416105-5F719213-CB4A-4A9E-8162-297AC1628667Q33425190-CFFF4BDB-A260-463A-BFC6-67230C963D28Q33432949-E686F83D-82A6-4957-9665-3CBA30CD77CAQ33433893-549C8DCD-E750-42C6-92F8-E8E396349766Q34256126-45A521A0-A4FB-4196-9112-F5B8A6AC3A70Q35571044-997FA186-DE11-4B12-B593-6AE63AC12CD3Q36115692-BD141D0A-2F18-4717-80DF-5E5BFE4CDD4CQ36274834-C44B699D-CDFC-4655-9B21-D9CBEE67021AQ36470302-DA6F5E3F-C2CC-4F2B-8F97-364277B9489FQ36548064-DBED9E9F-A1C7-4731-9E84-A1F953A0B42BQ36595921-8262EDDB-CDB3-4A48-941C-31EE3E0B03EEQ36671445-19546F4B-0C03-424C-A08E-70E684D00D6AQ36815262-CA3D9571-64D7-4685-B25D-26CFE37C65B0Q37158445-28236F70-8842-4473-8BDB-E911456A393DQ37199819-009EED2D-E933-4A7C-B431-94E051EE7EE1Q37275721-66B1AC3C-6870-48DD-BF20-57AD4F490421Q37397995-9DF7AEEA-22AE-4025-B5A3-E52C8EE335B0Q37410632-C553E1D2-AA2F-45A2-AE5B-8F642C87A37DQ37427124-A59BEBE4-F132-4B4A-854A-1A73CB816E35Q37615678-8DED5D05-CDDA-4CBF-8EB8-4B6CFD34104AQ37633986-6C2E2190-52EF-41F1-AB92-B23E70910EB9Q38068534-0AA8982D-7FD0-4404-8BD9-C8EB7312D6D5Q38103251-64229FA6-C7AB-4E48-BA49-ED36B8C6B812
P2860
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
An open-label, single-arm, pha ...... ously treated with bortezomib.
@ast
An open-label, single-arm, pha ...... ously treated with bortezomib.
@en
An open-label, single-arm, pha ...... ously treated with bortezomib.
@nl
type
label
An open-label, single-arm, pha ...... ously treated with bortezomib.
@ast
An open-label, single-arm, pha ...... ously treated with bortezomib.
@en
An open-label, single-arm, pha ...... ously treated with bortezomib.
@nl
prefLabel
An open-label, single-arm, pha ...... ously treated with bortezomib.
@ast
An open-label, single-arm, pha ...... ously treated with bortezomib.
@en
An open-label, single-arm, pha ...... ously treated with bortezomib.
@nl
P2093
P2860
P1476
An open-label, single-arm, pha ...... ously treated with bortezomib.
@en
P2093
Alexander Keith Stewart
Alvin F Wong
Andrew Belch
Andrzej J Jakubowiak
David S Siegel
Kevin McDonagh
Lori A Kunkel
Michael Wang
Nizar Bahlis
P2860
P304
P356
10.1111/J.1365-2141.2012.09232.X
P407
P577
2012-07-30T00:00:00Z